چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | علی احمدعلی پور |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | روانپزشکی و علوم رفتاری |
| کد مقاله | 78014 |
| عنوان فارسی مقاله | سیستم اندوکانابینوئید: هدف جدید در درمان صرع |
| عنوان لاتین مقاله | Endocannabinoid system: novel target in the treatment of the epilepsy |
| نوع ارائه | پوستر |
| عنوان کنگره / همایش | چهارمین کنگره بین المللی و بیست و پنجمین کنگره فیزیولوژی و فارماکولوژی |
| نوع کنگره / همایش | بین المللی |
| کشور محل برگزاری کنگره/ همایش | Iran (Islamic Republic) |
| شهر محل برگزاری کنگره/ همایش | تهران |
| سال انتشار/ ارائه شمسی | 1399 |
| سال انتشار/ارائه میلادی | 2021 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1400/07/28 الی 1400/07/30 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | https://cong25.phypha.ir/ |
| آدرس علمی (Affiliation) نویسنده متقاضی | Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. |
| نویسنده | نفر چندم مقاله |
|---|---|
| لیلا حسین زاده انور | چهارم |
| فاطمه رضائیان فرح آبادی | دوم |
| علی احمدعلی پور | سوم |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Introduction: Treatment-refractory epilepsy remains an important clinical problem. The brain’s endocannabinoid system which is activated by marijuana or endogenous homologous provides on-demand protection against the convulsive activity. Recently, there is considerable interest by the public and physicians in using medical marijuana or its derivatives to treat seizures. There is clinical evidence of success in diminishing seizure frequencies with cannabis derivatives such as marijuana, however, it remains largely illegal and may induce adverse consequences. Materials & Methods: This review article is the result of a review of research published in PubMed, Wiley, Science direct, ISI, Scopus, etc. between 2000 and 2021 about using cannabis and marijuana in the treatment of epilepsy, as well as the role of endocannabinoid system in the brain functions. Results: The CB1 receptors of the endocannabinoid system are expressed predominantly at presynaptic sites in GABAergic neurons. These receptors are present in high densities at neuronal terminals of the basal ganglia, cerebellum, hippocampus, neocortex, hypothalamus, and limbic cortex The agonistic activity of CB1 decreases cAMP by inhibition of adenylyl-cyclase, induces potassium efflux by stimulating A type and G-protein coupled inward rectifying potassium channels; also, it decreases calcium influx by inhibiting voltage-dependent N and P/Q-type calcium channels. This diminishes neuronal hyperexcitability and may attenuate seizure frequency Conclusion: Seizures affect the endocannabinoid system and the expression of CB1 protein in the animal hippocampus. This increases the expression of CB1 receptors in the CA1 through CA3 regions of the hippocampus and is postulated to be the mechanism of action for epilepsy control. For those whose seizures remain uncontrolled without alternative conventional interventions available, medical marijuana has received anecdotal support, but only on an empirical basis. Any clinical trial is appropriate only in selected refractory cases and only when strictly monitored by a physician. Being illegal in many jurisdictions remains a concern. |
| کلمات کلیدی | Endocannabinoid , epilepsy, Treatment-refractory , CB1 |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| Alipour and Haghgouie.jpg | 1400/11/16 | 426716 | دانلود |
| Endocannabinoid system novel target in the treatment of the epilepsy.jpg | 1400/11/16 | 348840 | دانلود |
